Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Chemotherapy With FOLFIRINOX Regimen or FLOT Regimen for Resectable Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial

NCT04393584 is registered in ClinicalTrials.gov with Blokhin's Russian Cancer Research Center as lead sponsor.

NCT NCT04393584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04393584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Chemotherapy With FOLFIRINOX Regimen or FLOT Regimen for Resectable Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial
Lead sponsor
Blokhin's Russian Cancer Research Center
Phase
Phase 2/3
Overall status
Unknown status
Start date
January 29, 2019
Completion date
January 1, 2026
Enrollment
538 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

docetaxel, fluoruracil, gastrointestinal neoplasms, irinotecan hydrochloride, oxaliplatin, stomach neoplasms